Emil Kuriakose, M.D.

Director

Dr. Kuriakose has served as a director since October 2026. Dr. Kuriakose most recently served as Chief Medical Officer of Terns Pharmaceuticals from 2023 to 2026, where he led clinical development, regulatory, medical affairs and portfolio strategy across the company’s clinical-stage programs, including TERN-701 in chronic myeloid leukemia and TERN-601 in obesity. He also contributed to business development activities leading to Terns’ acquisition by Merck & Co. in 2026. 

Prior to joining Terns, Dr. Kuriakose served as Chief Medical Officer and in other senior clinical development roles at Calithera Biosciences. Earlier in his career, he held positions of increasing responsibility at Novartis Oncology, where he contributed to the development, regulatory approval and launch of panobinostat for multiple myeloma. Dr. Kuriakose currently serves as an Entrepreneur in Residence at NextBio Capital and as Founder and Principal of Kure Consulting Services. 

Dr. Kuriakose received his M.D. from Stony Brook University School of Medicine and completed his residency in internal medicine at UT Southwestern Medical Center and a fellowship in hematology/oncology at Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center. The Board believes that Dr. Kuriakose’s extensive oncology drug development experience and clinical and regulatory expertise qualify him to serve as a member of our Board.

Independent Director